Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00641537 · ClinicalTrials.gov registry record · Phase 3
CLARITY Extension Study
A Phase 3 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 867
- Enrollment target
NCT00641537 is a Phase 3 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 867 participants.
The verdict
NCT00641537, a Phase 3 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 867 participants
- Enrollment target
Study Summary
The purpose of this extension trial was to further evaluate the safety and tolerability of oral cladribine in subjects who have previously completed treatment within Trial 25643 (CLARITY). This trial also explored clinical benefit of prolonged 192-week versus 96-week treatment.
Interventions
- DRUG Placebo
- DRUG Cladribine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 867 participants |
| Start Date | 2008-02-29 |
| Est. Completion | 2011-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00641537
The ClinicalTrials.gov registry entry for NCT00641537 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 867 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00641537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00641537 about?
NCT00641537 is a clinical study titled "CLARITY Extension Study". The purpose of this extension trial was to further evaluate the safety and tolerability of oral cladribine in subjects who have previously completed treatment within Trial 25643 (CLARITY). This trial also explored clinical benefit of prolonged 192-week versus 96-week treatment.
What is the current status of trial NCT00641537?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 867 participants. The study started on 2008-02-29. Estimated completion is 2011-12-31.
What interventions are being tested in trial NCT00641537?
The interventions under investigation include: Placebo (DRUG), Cladribine (DRUG).
Who is sponsoring clinical trial NCT00641537?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.